Efficacy of guselkumab in subpopulations of patients with moderate ‐to‐severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE 2 studies

ConclusionsThis analysis demonstrates a high degree of efficacy with guselkumab treatment compared with placebo at week 16 and with adalimumab at week 24 among broad subpopulations of patients with varying baseline demographics, disease characteristics, and previous psoriasis treatments.This article is protected by copyright. All rights reserved.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fbjd.16008

Source: British Journal of Dermatology - September 22, 2017 Category: Dermatology Authors: K. B. Gordon, A. Blauvelt, P. Foley, M. Song, Y. Wasfi, B. Randazzo, Y. K. Shen, Y. You, C. E. M. Griffiths Tags: Original Article Source Type: research